Abstract:Background: Currently, no satisfactory biomarkers are available to screen for lung cancer. Surface-Enhanced Laser Desorption/ionization Time-of- Flight Mass Spectrometry ProteinChip system (SELDI-TOF-MS) is one of the currently used techniques to identify biomarkers for cancers. The aim of this study is to explore the application of serum SELDI proteomic patterns to distinguish lung cancer patients from healthy individuals.Methods: A total of 208 serum samples, including 158 lung cancer patients and 50 healthy individuals, were randomly divided into a training set (including 11 sera from patients with stages I/II lung cancer, 63 from patients with stages III/IV lung cancer and 20 from healthy controls) and a blinded test set (including 43 sera from patients with stages I/II lung cancer, 41 from patients with stages III/IV lung cancer and 30 from healthy controls). All samples were analyzed by SELDI technology. The spectra were generated on weak cation exchange (WCX2) chips, and protein peaks clustering and classification analyses were made using Ciphergen Biomarker Wizard and Biomarker Pattern software, respectively. We additionally determined Cyfra21-1 and NSE in the 208 serum samples included in this study using an electrochemiluminescent immunoassay.Results: Five protein peaks at 11493, 6429, 8245, 5335 and 2538 Da were automatically chosen as a biomarker pattern in the training set. When the SELDI marker pattern was tested with the blinded test set, it yielded a sensitivity of 86.9%, a specificity of 80.0% and a positive predictive value of 92.4%. The sensitivities provided by Cyfra21-1 and NSE used individually or in combination were significantly lower than that of the SELDI marker pattern (P < 0.005 or 0.05, respectively). Based on the results of the test set, we found that the SELDI marker pattern showed a sensitivity of 91.4% in the detection of non-small cell lung cancers (NSCLC), which was significantly higher than that in the detection of small cell lung cancers (P < 0.05); The pattern also had a sensitivity of 79.1% in the detection of lung cancers in stages I/II.Conclusion: These results suggest that serum SELDI protein profiling can distinguish lung cancer patients, especially NSCLC patients, from normal subjects with relatively high sensitivity and specificity, and the SELDI- TOF- MS is a potential tool for the screening of lung cancer.

Serum diagnosis of diffuse large B-cell lymphomas and further identification of response to therapy using SELDI-TOF-MS and tree analysis patterning

Serum profiling by mass spectrometry combined with bioinformatics for the biomarkers discovery in diffuse large B-cell lymphoma

Rapid Identification of Novel Independent Serum Biomarkers in Diffuse Large B-cell Lymphoma

Application of Serum Seldi Proteomic Patterns in Diagnosis of Lung Cancer

Research on the biomarkers for the prediction of efficacy in first-line chemotherapy of metastatic colorectal cancer using SELDI-TOF-MS

SELDI-TOF MS profiling of serum for detection of laryngeal squamous cell carcinoma and the progression to lymph node metastasis

Analysis of differential expressed protein from SCLC patient serum

Correlation between small-cell lung cancer serum protein/peptides determined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemotherapy efficacy

Application of Serum Surface-Enhanced Laser Desorption/ionization Proteomic Patterns in Distinguishing Lung Cancer Patients from Healthy People.

Single-cell phenotypic profiling to identify a set of immune cell protein biomarkers for relapsed and refractory diffuse large B cell lymphoma: A single-center study

Biomarker Discovery and Identification from Non-Small Cell Lung Cancer Sera.

Study of Distinct Protein Profiles for Early Diagnosis of NSCLC Using LCM and SELDI-TOF-MS

Detection and Significance of Serum Protein Markers of Small-Cell Lung Cancer

Molecular Biomarker Exploration of Rituximab plus CHOP Therapy in Real-World Diffuse Large B-Cell Lymphoma Patients

Identification of Candidate Molecular Markers Predicting Chemotherapy Resistance in Non-Small Cell Lung Cancer

[Analysis of Serum Protein Fingerprints on Non-Small Cell Lung Cancer Lymphatic Metastasis].

[Surface Enhanced Laser Desorption/ionization Time-of-flight Mass Spectrometry Profiling of Serum in Detection of Laryngeal Squamous Cell Carcinoma and the Progression to Lymph Node Metastasis].

A Serum Proteomic Pattern for the Detection of Colorectal Adenocarcinoma Using Surface Enhanced Laser Desorption and Ionization Mass Spectrometry

Proteomic biomarkers predicting lymph node involvement in serum of cervical cancer patients. Limitations of SELDI-TOF MS

Identification of Novel Low Molecular Weight Serum Peptidome Biomarkers for Non‐Small Cell Lung Cancer (NSCLC)

Diagnostic and Prognostic Application of Proteomic Patterns in Breast Cancer